Kazimieras Maneikis

Dr. Kazimieras Maneikis


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in The Lancet Haematology
Verified
Journal Article
Closed access
KMKazimieras Maneikis
Kazimieras Maneikis
KŠKarolis Šablauskas
Karolis Šablauskas
URUgnė Ringelevičiūtė
Ugnė Ringelevičiūtė
VVVilmantė Vaitekėnaitė
Vilmantė Vaitekėnaitė
RČRita Čekauskienė
Rita Čekauskienė
LGLaimonas Griškevičius
Laimonas Griškevičius

1 February 2021 in IJC Heart & Vasculature
Verified
Journal Article
Open access
KMKazimieras Maneikis
Kazimieras Maneikis
URUgne Ringeleviciute
Ugne Ringeleviciute
JBJustinas Bacevicius
Justinas Bacevicius
EDEgle Dieninyte-Misiune
Egle Dieninyte-Misiune
EBEmilija Burokaite
Emilija Burokaite
LGLaimonas Griskevicius
Laimonas Griskevicius
To assess cardiac safety in COVID-19 patients treated with the combination of Hydroxychloroquine and Azithromycin using arrhythmia risk management plan. We retrospectively examined arrhythmia safety of treatment with Hydroxychloroquine and Azithromycin in the setting of pre-defined arrhythmia risk management plan. The data was analyzed using R statistical package version 4.0.0. A two-tailed p-value<0.05 was considered significant. 81 patients were included from March 23rd to May 10th 2020. The median age was 59 years, 58.0% were female. The majority of the study population (82.7%) had comorbidities, 98.8% had radiological signs of pneumonia. Fourteen patients (17.3%) experienced QTc ≥ 480 ms and 16 patients (19.8%) had an increase of QTc ≥ 60 ms. Seven patients (8.6%) had QTc prolongation of ≥ 500 ms. The treatment was discontinued in 4 patients (4.9%). None of the patients developed ventricular tachycardia. The risk factors significantly associated with QTc ≥ 500 ms were hypokalemia (p = 0.032) and use of diuretics during the treatment (p = 0.020). Three patients (3.7%) died, the cause of death was bacterial superinfection with septic shock in two patients, and disseminated intravascular coagulation with multiple organ failure in one patient. None of these deaths were associated with cardiac arrhythmias. We recorded a low incidence of QTc prolongation ≥ 500 ms and no ventricular tachycardia events in COVID-19 patients treated with Hydroxychloroquine and Azithromycin using cardiac arrhythmia risk management plan.

1 October 2025 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
KMKazimieras Maneikis
Kazimieras Maneikis
EKEvelien Krumb
Evelien Krumb
CHCedric Hermans
Cedric Hermans
Hemophilia is an inherited bleeding disorder characterized by a deficiency in clotting factor, leading to impaired thrombin generation, bleeding complications, and long-term morbidity that severely impacts patients’ quality of life. Recent advancements in treatment have significantly empowered the hemophilia community, improving disease control, reducing treatment burden, expanding access to care, and lowering the risks of lifelong complications. These advancements have continually elevated the goals of hemophilia care. The latest innovations have introduced a new ambition: the “normalization” of life for persons with hemophilia. This aspiration is both desirable and promising, with the potential to greatly enhance patients’ quality of life and achieve equitable health outcomes. However, it is crucial for the entire community to first determine and define what constitutes an optimal and realistically achievable level of hemostasis normalization using current and emerging therapies. The significant psychosocial impact of hemophilia underscores the importance of targeting not only hemostasis normalization but also life normalization. This approach prioritizes reducing treatment burden and restoring mental well-being. Novel standardized tools are urgently needed to appropriately complement novel therapies, as traditional bleeding rate-based outcome metrics are becoming inadequate for assessing treatment superiority objectively. The potential risks of striving for normalized hemostasis must also be carefully considered. Moreover, specific needs and challenges associated with normalization must be addressed, particularly for carriers and women and girls with hemophilia.

1 December 2021 in Leukemia Research
Verified
Journal Article
Closed access
JDJustinas Daraskevicius
Justinas Daraskevicius
VEVeronika Everatt
Veronika Everatt
VVVilmante Vaitekenaite
Vilmante Vaitekenaite
URUgne Ringeleviciute
Ugne Ringeleviciute
KMKazimieras Maneikis
Kazimieras Maneikis
AŽAndrius Žučenka
Andrius Žučenka

8 September 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
GHGerd Herold
Gerd Herold
VJViktoras Justickis
Viktoras Justickis
VMVytė Valerija Maneikienė
Vytė Valerija Maneikienė
KMKazimieras Maneikis
Kazimieras Maneikis
PTPaulius Trinkauskas
Paulius Trinkauskas
KPKarina Palkova
Karina Palkova
Background: Despite more than 25 years of intensive effort following the landmark “To Err Is Human” report, conventional top-down medical error prevention strategies, grounded in the Safety-I paradigm, have largely failed to reduce patient harm. This persistent shortcoming underscores the need for a new prevention model. The medical literature contains an extensive yet systematically underutilized body of physician-generated experiential knowledge on “clinical pitfalls”—specific high-risk scenarios in which errors are likely to occur. This resource presents an opportunity for a novel, physician-driven approach to medical error prevention. The present paper proposes and evaluates such a model, grounded in the principles of Safety-II and translational medicine. Methods: The methodology involved a three-part conceptual analysis: (1) a critical review of the literature assessing the effectiveness of established error prevention strategies, (2) a quantitative bibliometric analysis of the PubMed database to determine the volume and temporal trends of publications on “clinical pitfalls”, and (3) a conceptual synthesis to design a novel physician-driven error prevention model. Each method is described in detail at the beginning of its respective section. Results: The literature review confirms the limited effectiveness of existing top-down safety initiatives, particularly in complex domains such as diagnosis and treatment. The bibliometric analysis identified more than 43,000 publications containing the keyword “pitfall,” with a sustained and significant upward trend in annual publications over the past three decades. The conceptual synthesis demonstrates that a physician-driven system—centered on a “Pitfall Bank”—addresses core weaknesses of current strategies, including unreliable data, heterogeneous knowledge, and cognitive biases. Structured as a circular translational mechanism, the proposed system facilitates a continuous cycle of practice-based problem identification and science-informed solution implementation. Conclusions: A physician-driven prevention system, architected as a translational engine, offers a promising and sustainable strategy to overcome the current impasse in medical error reduction and create a more resilient and adaptive healthcare system.

1 September 2016 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
ABAugustinas Bausys
Augustinas Bausys
DKD. Klimas
D. Klimas
KMKazimieras Maneikis
Kazimieras Maneikis
KPK. Pauža
K. Pauža
ESE. Sangaila
E. Sangaila
RBR. Baušys
R. Baušys